PARP1 and small cell lung carcinoma: A phase II trial (NCT04701307) assessed the effectiveness of a combination therapy involving the anti-PD-1 monoclonal antibody dostarlimab along with the PARP inhibitor niraparib in patients with extensive-stage SCLC who had previously undergone treatment [10,203].